Sujatha Venkataraman
Concepts (315)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medulloblastoma | 16 | 2023 | 172 | 2.870 |
Why?
| Cerebellar Neoplasms | 12 | 2023 | 131 | 2.270 |
Why?
| Glioma | 9 | 2023 | 296 | 1.760 |
Why?
| Cell Proliferation | 21 | 2023 | 2194 | 0.990 |
Why?
| Gene Expression Regulation, Neoplastic | 16 | 2022 | 1147 | 0.970 |
Why?
| Superoxide Dismutase | 12 | 2016 | 332 | 0.960 |
Why?
| Nuclear Proteins | 6 | 2023 | 594 | 0.930 |
Why?
| Radiation Tolerance | 6 | 2022 | 92 | 0.930 |
Why?
| Rhabdoid Tumor | 4 | 2022 | 79 | 0.810 |
Why?
| Polycomb Repressive Complex 1 | 2 | 2020 | 40 | 0.800 |
Why?
| Cell Line, Tumor | 23 | 2023 | 2751 | 0.790 |
Why?
| Cell Cycle Proteins | 8 | 2022 | 553 | 0.740 |
Why?
| Antineoplastic Agents | 7 | 2022 | 1893 | 0.700 |
Why?
| Reactive Oxygen Species | 8 | 2022 | 549 | 0.690 |
Why?
| Teratoma | 4 | 2022 | 92 | 0.670 |
Why?
| Proto-Oncogene Proteins c-myc | 3 | 2021 | 114 | 0.630 |
Why?
| Central Nervous System Neoplasms | 2 | 2023 | 125 | 0.550 |
Why?
| MicroRNAs | 2 | 2012 | 607 | 0.500 |
Why?
| Proto-Oncogene Proteins | 4 | 2022 | 609 | 0.500 |
Why?
| Brain Stem Neoplasms | 3 | 2021 | 86 | 0.490 |
Why?
| Pyrazoles | 7 | 2022 | 362 | 0.480 |
Why?
| Apoptosis | 14 | 2022 | 2377 | 0.480 |
Why?
| Cellular Senescence | 3 | 2019 | 153 | 0.460 |
Why?
| Neoplastic Stem Cells | 2 | 2014 | 331 | 0.440 |
Why?
| Protein-Tyrosine Kinases | 4 | 2020 | 396 | 0.440 |
Why?
| Cerebellum | 3 | 2012 | 200 | 0.420 |
Why?
| Superoxides | 4 | 2010 | 215 | 0.400 |
Why?
| Tumor Cells, Cultured | 8 | 2020 | 850 | 0.390 |
Why?
| Prostatic Neoplasms | 3 | 2016 | 927 | 0.370 |
Why?
| Repressor Proteins | 2 | 2012 | 369 | 0.370 |
Why?
| Histones | 4 | 2020 | 540 | 0.370 |
Why?
| Aging | 1 | 2020 | 1631 | 0.370 |
Why?
| Transcription Factors | 3 | 2023 | 1528 | 0.360 |
Why?
| RNA, Messenger | 5 | 2014 | 2574 | 0.360 |
Why?
| Pyrimidines | 5 | 2017 | 376 | 0.360 |
Why?
| Intracellular Space | 1 | 2010 | 68 | 0.350 |
Why?
| Biomarkers, Tumor | 4 | 2020 | 1048 | 0.350 |
Why?
| Cell Cycle | 9 | 2017 | 546 | 0.340 |
Why?
| Cell Survival | 7 | 2017 | 1024 | 0.320 |
Why?
| Ependymoma | 2 | 2020 | 158 | 0.290 |
Why?
| Neoplasm Recurrence, Local | 2 | 2022 | 863 | 0.270 |
Why?
| Humans | 51 | 2023 | 115587 | 0.270 |
Why?
| Pyrimidinones | 4 | 2020 | 88 | 0.260 |
Why?
| Mice | 13 | 2022 | 15052 | 0.260 |
Why?
| Azepines | 3 | 2019 | 74 | 0.250 |
Why?
| NF-kappa B | 2 | 2019 | 639 | 0.240 |
Why?
| Blotting, Western | 5 | 2014 | 1153 | 0.240 |
Why?
| Oligonucleotide Array Sequence Analysis | 4 | 2016 | 746 | 0.240 |
Why?
| Brain Neoplasms | 3 | 2023 | 980 | 0.230 |
Why?
| Radiation, Ionizing | 2 | 2022 | 73 | 0.230 |
Why?
| Radiation | 2 | 2021 | 24 | 0.230 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 317 | 0.230 |
Why?
| Cell Transformation, Neoplastic | 2 | 2019 | 314 | 0.230 |
Why?
| Epigenomics | 2 | 2020 | 105 | 0.220 |
Why?
| Fever | 1 | 2004 | 280 | 0.220 |
Why?
| Genes, myc | 2 | 2020 | 47 | 0.210 |
Why?
| Cyclin-Dependent Kinase 6 | 2 | 2012 | 37 | 0.210 |
Why?
| Molecular Targeted Therapy | 2 | 2016 | 348 | 0.210 |
Why?
| Chromatin | 3 | 2020 | 429 | 0.210 |
Why?
| Hydrogen Peroxide | 6 | 2008 | 287 | 0.210 |
Why?
| von Willebrand Diseases | 1 | 2022 | 11 | 0.210 |
Why?
| Single-Cell Analysis | 2 | 2022 | 187 | 0.210 |
Why?
| Mutation | 3 | 2023 | 3364 | 0.210 |
Why?
| von Willebrand Factor | 1 | 2022 | 56 | 0.200 |
Why?
| Xenograft Model Antitumor Assays | 4 | 2020 | 704 | 0.200 |
Why?
| Child | 13 | 2023 | 18488 | 0.200 |
Why?
| Animals | 15 | 2022 | 32102 | 0.200 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2016 | 249 | 0.200 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 57 | 0.200 |
Why?
| Receptor, trkC | 1 | 2021 | 10 | 0.190 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 214 | 0.190 |
Why?
| Piperazines | 3 | 2022 | 314 | 0.190 |
Why?
| Receptor, trkB | 1 | 2021 | 28 | 0.190 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 171 | 0.180 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 59 | 0.180 |
Why?
| Receptor, EphB4 | 1 | 2020 | 23 | 0.180 |
Why?
| Ephrin-B2 | 1 | 2020 | 35 | 0.180 |
Why?
| Mice, Nude | 3 | 2020 | 639 | 0.180 |
Why?
| RNA, Small Interfering | 4 | 2022 | 544 | 0.170 |
Why?
| Transcriptional Elongation Factors | 1 | 2020 | 33 | 0.170 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 59 | 0.170 |
Why?
| Astrocytoma | 1 | 2020 | 109 | 0.170 |
Why?
| Receptors, Nerve Growth Factor | 1 | 2019 | 15 | 0.170 |
Why?
| Karyopherins | 1 | 2019 | 15 | 0.170 |
Why?
| DNA Repair | 1 | 2021 | 190 | 0.170 |
Why?
| Cell Differentiation | 4 | 2020 | 1700 | 0.170 |
Why?
| Deoxycytidine | 1 | 2020 | 140 | 0.160 |
Why?
| Child, Preschool | 7 | 2021 | 9133 | 0.160 |
Why?
| SMARCB1 Protein | 1 | 2019 | 16 | 0.160 |
Why?
| Pteridines | 2 | 2016 | 21 | 0.160 |
Why?
| Sulfonamides | 1 | 2022 | 447 | 0.160 |
Why?
| Membrane Glycoproteins | 1 | 2021 | 431 | 0.160 |
Why?
| Lysine | 1 | 2020 | 245 | 0.160 |
Why?
| Promoter Regions, Genetic | 5 | 2017 | 1122 | 0.160 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 449 | 0.150 |
Why?
| Enzyme Inhibitors | 4 | 2020 | 757 | 0.150 |
Why?
| Gene Expression Profiling | 3 | 2014 | 1536 | 0.150 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 195 | 0.150 |
Why?
| Cisplatin | 2 | 2016 | 263 | 0.150 |
Why?
| Glioblastoma | 1 | 2020 | 253 | 0.150 |
Why?
| Everolimus | 1 | 2017 | 63 | 0.150 |
Why?
| Recombinational DNA Repair | 1 | 2017 | 9 | 0.150 |
Why?
| Triazoles | 2 | 2019 | 132 | 0.140 |
Why?
| Morpholines | 1 | 2017 | 103 | 0.140 |
Why?
| Phthalazines | 1 | 2017 | 39 | 0.140 |
Why?
| Immunophenotyping | 1 | 2017 | 277 | 0.140 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.140 |
Why?
| Radiation-Sensitizing Agents | 1 | 2016 | 38 | 0.140 |
Why?
| Neoplasm Invasiveness | 2 | 2020 | 445 | 0.140 |
Why?
| Cell Movement | 3 | 2020 | 867 | 0.140 |
Why?
| E1A-Associated p300 Protein | 1 | 2016 | 8 | 0.130 |
Why?
| Mitochondria | 3 | 2006 | 750 | 0.130 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2016 | 82 | 0.130 |
Why?
| Glutathione Peroxidase | 2 | 2006 | 42 | 0.130 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 400 | 0.130 |
Why?
| Metalloporphyrins | 1 | 2016 | 106 | 0.130 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2016 | 128 | 0.130 |
Why?
| Tumor Suppressor Proteins | 1 | 2017 | 286 | 0.130 |
Why?
| DNA Methylation | 3 | 2021 | 498 | 0.120 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2012 | 59 | 0.120 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 930 | 0.120 |
Why?
| Survival Rate | 2 | 2020 | 1650 | 0.120 |
Why?
| Neural Stem Cells | 2 | 2012 | 115 | 0.120 |
Why?
| Up-Regulation | 3 | 2016 | 820 | 0.120 |
Why?
| Myocytes, Smooth Muscle | 2 | 2016 | 239 | 0.120 |
Why?
| Protein Processing, Post-Translational | 1 | 2016 | 401 | 0.110 |
Why?
| Prognosis | 3 | 2020 | 3339 | 0.110 |
Why?
| Cathepsin B | 1 | 2012 | 14 | 0.110 |
Why?
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.110 |
Why?
| Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 37 | 0.110 |
Why?
| Argonaute Proteins | 1 | 2012 | 28 | 0.110 |
Why?
| 3' Untranslated Regions | 1 | 2012 | 136 | 0.100 |
Why?
| Aurora Kinases | 1 | 2012 | 28 | 0.100 |
Why?
| Early Growth Response Protein 1 | 1 | 2011 | 28 | 0.100 |
Why?
| Aurora Kinase A | 1 | 2012 | 51 | 0.100 |
Why?
| Xanthine Oxidase | 1 | 2011 | 72 | 0.100 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 157 | 0.090 |
Why?
| Dioxygenases | 1 | 2011 | 25 | 0.090 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2017 | 538 | 0.090 |
Why?
| Signal Transduction | 4 | 2012 | 4541 | 0.090 |
Why?
| Cyclin D1 | 2 | 2008 | 61 | 0.090 |
Why?
| CpG Islands | 1 | 2011 | 118 | 0.090 |
Why?
| Male | 11 | 2021 | 55949 | 0.090 |
Why?
| Neoplasm Grading | 2 | 2021 | 244 | 0.090 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2012 | 443 | 0.090 |
Why?
| Brain | 3 | 2023 | 2370 | 0.080 |
Why?
| DNA-Binding Proteins | 2 | 2016 | 1316 | 0.080 |
Why?
| Drug Screening Assays, Antitumor | 2 | 2021 | 180 | 0.080 |
Why?
| Female | 12 | 2021 | 59913 | 0.080 |
Why?
| Neoplasm Proteins | 1 | 2012 | 385 | 0.080 |
Why?
| Carrier Proteins | 1 | 2012 | 701 | 0.080 |
Why?
| Hypoxia | 2 | 2011 | 937 | 0.080 |
Why?
| Tumor Stem Cell Assay | 2 | 2006 | 33 | 0.080 |
Why?
| Free Radicals | 2 | 2006 | 98 | 0.080 |
Why?
| Quinazolines | 2 | 2022 | 241 | 0.080 |
Why?
| Down-Regulation | 1 | 2010 | 601 | 0.070 |
Why?
| Catalase | 2 | 2006 | 118 | 0.070 |
Why?
| Energy Metabolism | 1 | 2012 | 715 | 0.070 |
Why?
| Transfection | 3 | 2019 | 866 | 0.070 |
Why?
| Dicumarol | 1 | 2006 | 2 | 0.070 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 156 | 0.070 |
Why?
| G2 Phase | 1 | 2006 | 31 | 0.070 |
Why?
| Transcription Factor AP-2 | 1 | 2006 | 81 | 0.070 |
Why?
| Base Sequence | 1 | 2010 | 2114 | 0.070 |
Why?
| Acetylcysteine | 1 | 2007 | 144 | 0.070 |
Why?
| Transcriptome | 2 | 2022 | 736 | 0.070 |
Why?
| Mouth Neoplasms | 1 | 2006 | 70 | 0.070 |
Why?
| Keratinocytes | 1 | 2006 | 215 | 0.060 |
Why?
| Hypertension, Pulmonary | 1 | 2016 | 1749 | 0.060 |
Why?
| Aconitate Hydratase | 1 | 2004 | 17 | 0.060 |
Why?
| Phenotype | 1 | 2012 | 2829 | 0.060 |
Why?
| Cell Hypoxia | 1 | 2005 | 220 | 0.060 |
Why?
| Phosphorylation | 2 | 2020 | 1571 | 0.060 |
Why?
| Epigenesis, Genetic | 2 | 2020 | 526 | 0.060 |
Why?
| DNA Damage | 2 | 2017 | 357 | 0.060 |
Why?
| Lipid Peroxidation | 1 | 2004 | 138 | 0.060 |
Why?
| Fatty Acids, Unsaturated | 1 | 2004 | 85 | 0.060 |
Why?
| Membrane Potentials | 1 | 2004 | 251 | 0.060 |
Why?
| Ultraviolet Rays | 1 | 2006 | 372 | 0.060 |
Why?
| Androgens | 1 | 2005 | 165 | 0.050 |
Why?
| Cells, Cultured | 4 | 2016 | 3914 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2005 | 503 | 0.050 |
Why?
| Tyrosine | 1 | 2023 | 219 | 0.050 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2023 | 147 | 0.050 |
Why?
| Hot Temperature | 1 | 2004 | 303 | 0.050 |
Why?
| Weibel-Palade Bodies | 1 | 2022 | 3 | 0.050 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 41 | 0.050 |
Why?
| Spheroids, Cellular | 2 | 2012 | 57 | 0.050 |
Why?
| Gene Ontology | 1 | 2021 | 47 | 0.050 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2022 | 90 | 0.050 |
Why?
| Oxidation-Reduction | 3 | 2011 | 924 | 0.050 |
Why?
| Transcriptional Activation | 2 | 2017 | 340 | 0.050 |
Why?
| Carcinoma, Squamous Cell | 1 | 2006 | 577 | 0.050 |
Why?
| Immunotherapy, Adoptive | 1 | 2023 | 194 | 0.050 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 388 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 2 | 2017 | 1870 | 0.050 |
Why?
| Macrophages, Alveolar | 1 | 2004 | 357 | 0.050 |
Why?
| Hedgehog Proteins | 1 | 2022 | 172 | 0.050 |
Why?
| Fatal Outcome | 1 | 2021 | 286 | 0.040 |
Why?
| Biopsy | 1 | 2023 | 1056 | 0.040 |
Why?
| Pancreatic Neoplasms | 1 | 2006 | 722 | 0.040 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2023 | 630 | 0.040 |
Why?
| Tumor Microenvironment | 1 | 2022 | 431 | 0.040 |
Why?
| Airway Resistance | 1 | 1999 | 33 | 0.040 |
Why?
| Cell Self Renewal | 1 | 2019 | 49 | 0.040 |
Why?
| Pneumonia | 1 | 2004 | 576 | 0.040 |
Why?
| Bone Morphogenetic Proteins | 1 | 2019 | 133 | 0.040 |
Why?
| Breast Neoplasms | 3 | 2006 | 1872 | 0.040 |
Why?
| Time Factors | 2 | 2006 | 6165 | 0.040 |
Why?
| Cohort Studies | 2 | 2021 | 4944 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 57 | 0.040 |
Why?
| Oxidative Stress | 3 | 2011 | 1093 | 0.040 |
Why?
| Computer Simulation | 1 | 2021 | 881 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 99 | 0.040 |
Why?
| Neoplasms | 1 | 2011 | 2118 | 0.040 |
Why?
| Benzamides | 1 | 2017 | 168 | 0.040 |
Why?
| Adolescent | 5 | 2021 | 17889 | 0.040 |
Why?
| Benzodiazepinones | 1 | 2016 | 14 | 0.030 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 23 | 0.030 |
Why?
| Electron Spin Resonance Spectroscopy | 2 | 2007 | 87 | 0.030 |
Why?
| Enzyme Repression | 1 | 2016 | 8 | 0.030 |
Why?
| Urea | 1 | 2016 | 69 | 0.030 |
Why?
| Radiation-Protective Agents | 1 | 2016 | 26 | 0.030 |
Why?
| Flow Cytometry | 2 | 2012 | 1083 | 0.030 |
Why?
| Thiophenes | 1 | 2016 | 109 | 0.030 |
Why?
| Acetylation | 1 | 2016 | 212 | 0.030 |
Why?
| Mitosis | 1 | 2016 | 164 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2023 | 1756 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2017 | 344 | 0.030 |
Why?
| Respiratory Insufficiency | 1 | 1999 | 292 | 0.030 |
Why?
| Drug Synergism | 1 | 2016 | 317 | 0.030 |
Why?
| HeLa Cells | 1 | 2016 | 567 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2020 | 1970 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2016 | 621 | 0.030 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2016 | 199 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2016 | 815 | 0.030 |
Why?
| Young Adult | 2 | 2021 | 10470 | 0.030 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2006 | 274 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2016 | 526 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 732 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 2016 | 420 | 0.030 |
Why?
| Fibroblasts | 2 | 2008 | 839 | 0.030 |
Why?
| Kinetics | 2 | 2006 | 1569 | 0.030 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2012 | 130 | 0.030 |
Why?
| Colony-Forming Units Assay | 1 | 2012 | 90 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 193 | 0.030 |
Why?
| Colorado | 1 | 2022 | 4113 | 0.030 |
Why?
| Luciferases | 1 | 2012 | 140 | 0.030 |
Why?
| Gene Knockout Techniques | 1 | 2012 | 99 | 0.030 |
Why?
| Genome, Human | 1 | 2014 | 352 | 0.030 |
Why?
| Microarray Analysis | 1 | 2012 | 119 | 0.020 |
Why?
| Tubulin | 1 | 2012 | 123 | 0.020 |
Why?
| Embryo, Mammalian | 1 | 2012 | 214 | 0.020 |
Why?
| Extracellular Space | 1 | 2011 | 122 | 0.020 |
Why?
| Metabolic Networks and Pathways | 1 | 2012 | 168 | 0.020 |
Why?
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2011 | 20 | 0.020 |
Why?
| Gene Expression | 1 | 2016 | 1435 | 0.020 |
Why?
| RNA Interference | 1 | 2012 | 438 | 0.020 |
Why?
| Adenosine | 1 | 2012 | 203 | 0.020 |
Why?
| Mammals | 1 | 2012 | 251 | 0.020 |
Why?
| Gene Silencing | 1 | 2011 | 175 | 0.020 |
Why?
| MAP Kinase Signaling System | 1 | 2011 | 275 | 0.020 |
Why?
| Animals, Newborn | 1 | 2011 | 780 | 0.020 |
Why?
| Genomics | 1 | 2014 | 645 | 0.020 |
Why?
| Pyridines | 1 | 2012 | 425 | 0.020 |
Why?
| Cattle | 1 | 2011 | 935 | 0.020 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1361 | 0.020 |
Why?
| Cyclin B1 | 1 | 2008 | 5 | 0.020 |
Why?
| Cyclin B | 1 | 2008 | 13 | 0.020 |
Why?
| Protein Kinase Inhibitors | 1 | 2014 | 790 | 0.020 |
Why?
| Rats | 1 | 2016 | 5034 | 0.020 |
Why?
| Oxygen | 1 | 2012 | 837 | 0.020 |
Why?
| Dicarbethoxydihydrocollidine | 1 | 2007 | 1 | 0.020 |
Why?
| Models, Molecular | 1 | 2012 | 1390 | 0.020 |
Why?
| G1 Phase | 1 | 2007 | 68 | 0.020 |
Why?
| Glucose | 1 | 2012 | 904 | 0.020 |
Why?
| NIH 3T3 Cells | 1 | 2007 | 137 | 0.020 |
Why?
| Uncoupling Agents | 1 | 2006 | 1 | 0.020 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2006 | 31 | 0.020 |
Why?
| Glutathione Disulfide | 1 | 2006 | 27 | 0.020 |
Why?
| Cell Line, Transformed | 1 | 2006 | 133 | 0.020 |
Why?
| Bromodeoxyuridine | 1 | 2006 | 73 | 0.020 |
Why?
| Electron Transport | 1 | 2006 | 112 | 0.020 |
Why?
| Ceramides | 1 | 2006 | 96 | 0.020 |
Why?
| Adenoviruses, Human | 1 | 2005 | 24 | 0.020 |
Why?
| RNA | 1 | 2012 | 819 | 0.020 |
Why?
| Pulmonary Artery | 1 | 2011 | 1031 | 0.020 |
Why?
| Chronic Disease | 1 | 2011 | 1598 | 0.020 |
Why?
| Case-Control Studies | 1 | 2012 | 3022 | 0.020 |
Why?
| Glutathione | 1 | 2006 | 303 | 0.020 |
Why?
| Amitrole | 1 | 2004 | 9 | 0.010 |
Why?
| Asbestos | 1 | 2004 | 20 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2006 | 1243 | 0.010 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 263 | 0.010 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2004 | 277 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2011 | 3580 | 0.010 |
Why?
| Antioxidants | 1 | 2005 | 533 | 0.010 |
Why?
| Monocytes | 1 | 2004 | 507 | 0.010 |
Why?
| Cell Line | 1 | 2006 | 2651 | 0.010 |
Why?
| Enzyme Activation | 1 | 2002 | 793 | 0.010 |
Why?
| Adult | 2 | 2016 | 30718 | 0.010 |
Why?
| Adenocarcinoma | 1 | 2005 | 799 | 0.010 |
Why?
| Unconsciousness | 1 | 1999 | 18 | 0.010 |
Why?
| Lung Compliance | 1 | 1999 | 49 | 0.010 |
Why?
| Lung Diseases, Obstructive | 1 | 1999 | 40 | 0.010 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1137 | 0.010 |
Why?
| Tidal Volume | 1 | 1999 | 74 | 0.010 |
Why?
| Positive-Pressure Respiration | 1 | 1999 | 68 | 0.010 |
Why?
| Nitric Oxide | 1 | 2002 | 832 | 0.010 |
Why?
| Intubation, Intratracheal | 1 | 1999 | 215 | 0.010 |
Why?
| Middle Aged | 1 | 2016 | 26999 | 0.010 |
Why?
| Lung Diseases, Interstitial | 1 | 1999 | 520 | 0.010 |
Why?
| Lung | 1 | 2004 | 3672 | 0.010 |
Why?
| Infant, Newborn | 1 | 1999 | 5077 | 0.000 |
Why?
| Infant | 1 | 1999 | 7979 | 0.000 |
Why?
|
|
Venkataraman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|